Cytosorbents (CTSO) Capital Expenditures Growth (1y) (2012 - 2026)
Cytosorbents (CTSO) Capital Expenditures Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | -17.56% |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 34.96% |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | -6.72% |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | -5.35% |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | 15.89% |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | -43.42% |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -47.73% |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | -11.95% |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 27.22% |
| 10 | Cytosorbents | 25.72 Mn | 20.92 Mn | 6.13 Mn | 450.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 450.00% |
| Dec 31, 2025 | 56.52% |
| Sep 30, 2025 | -88.82% |
| Jun 30, 2025 | 107.76% |
| Mar 31, 2025 | -95.57% |
| Dec 31, 2024 | -27.75% |
| Sep 30, 2024 | 6.74% |
| Jun 30, 2024 | -94.07% |
| Dec 31, 2023 | -98.36% |
| Sep 30, 2023 | 102.87% |
| Jun 30, 2023 | -90.31% |
| Dec 31, 2022 | 59.47% |
| Sep 30, 2022 | -306.94% |
| Jun 30, 2022 | 292.92% |
| Mar 31, 2022 | 398.21% |
| Dec 31, 2021 | 2,147.60% |
| Sep 30, 2021 | -629.52% |
| Jun 30, 2021 | 874.08% |
| Mar 31, 2021 | 81.97% |
| Dec 31, 2020 | 15.10% |